

Sunny Optical (2382 HK)

2H22 first take: weakness in-line; awaiting recovery

Sunny's 2H22 net profit decline of 54% YoY is in-line with expectations, while revenue exceeds our/consensus estimates by 25%/9%, mainly due to better ASP and product mix. 2H22 GPM came in at 19.0%, vs 20.8% in 1H22 due to lower HCM/HLS/VLS GPM. We expect 1H23E outlook will remain under pressure given on-going inventory correction, smartphone demand recovery uncertainty and global EV sales slowdown. Despite bumpy recovery in 2023, we are positive on VCM/periscope/AR/VR to drive growth in longer term. Trading at 24.2x FY23E P/E, we think the stock is fairly valued. Analyst briefing will be hosted at 10:30am today, and we will look for 2023 shipment/ASP guidance and business outlook on AR/VR/auto CCM business.

- 2H22 weakness in-line; HCM/HLS margin under pressure. 2H22 revenue/NP declined 8%/54% YoY, largely in-line with expectations. GPM dropped to 19.0% in 2H22 from 21.5% in 2H21, dragged by HLS GPM decline of 4.4ppts and HCM GPM drop of 2.7ppts. Despite weak shipment, HCM/VLS ASP came in better than expected, but we estimate HLS dropped 34% YoY/31% HoH, mainly due to competition and cam de-spec trend.
- A bumpy demand recovery in the near term. We expect HCM/HLS shipment weakness to persist into 1H23E on high base and inventory correction. We suggest to focus on management's 2023 shipment guidance during earnings call, which might give us some color on demand recovery in 2H23E. We noted that Q-Tech announced conservative capex plan on smartphone capacity expansion, which implies bumpy demand recovery in 2023 in our view.
- Key questions for mgmt. at investor meeting. 1) HLS market share and upgrade with US major customers; 2) periscope cam outlook in Android camp; 3) Sunny's view VLS demand given slower global auto sales 4) auto module order wins and capacity expansion; and 5) AR/VR outlook given major customer weakness.
- Maintain HOLD with TP of HK\$92.51. While we are positive on Sunny's industry leadership, product roadmap and opportunities in auto camera/VCM/AR/VR, we believe inventory destocking and high exposure to handset segment will remain the overhang for the stock. Trading at 24.2x FY23E P/E, we think the stock is fairly valued. Maintain HOLD with SOTP-based TP of HK\$92.51.

Earnings Summary

(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E				
Revenue (RMB mn)	38,002	37,497	29,813	32,213	37,781				
YoY growth (%)	0.4	(1.3)	(20.5)	8.0	17.3				
Net profit (RMB mn)	4,950.3	5,061.1	2,454.2	3,625.5	4,405.0				
YoY growth (%)	23.2	2.2	(51.5)	47.7	21.5				
EPS (Reported) (RMB)	4.47	4.57	2.20	3.26	3.96				
Consensus EPS (RMB)	0.00	4.57	2.71	3.76	4.86				
P/E (x)	25.5	38.3	35.8	24.2	19.9				
P/B (x)	7.4	9.2	3.8	3.3	2.9				
Yield (%)	0.6	0.5	0.5	0.8	1.0				
ROE (%)	33.5	26.8	11.2	14.9	16.0				
Net gearing (%)	(4.6)	(16.1)	(22.1)	(21.6)	(30.2)				
Source: Company data, Bloomberg, CMBIGM estimates									

HOLD (Maintain)

 Target Price
 HK\$92.51

 (Previous TP
 HK\$92.51)

 Up/Downside
 6.4%

 Current Price
 HK\$86.95

China Technology

Alex NG

(852) 3900 0881 alexng@cmbi.com.hk

Lily YANG, Ph.D (852) 3916 3716 lilyyang@cmbi.com.hk

Hanqing LI

lihanqing@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	98,730.0
Avg 3 mths t/o (HK\$ mn)	97.0
52w High/Low (HK\$)	144.60/67.55
Total Issued Shares (mn)	1097.0
Source: FactSet	

Shareholding Structure

Sun Xu Ltd	35.5%
JP Morgan Chase & Co	4.9%
Source: HKEx	

Share Performance

	Absolute	Relative
1-mth	-7.6%	-1.1%
3-mth	-4.4%	-4.7%
6-mth	-7.7%	-11.3%

Source: FactSet

12-mth Price Performance



Source: FactSet


Related Reports:

- 1) FY22E preview; Bumpy recovery in 2023 15 Mar 2023 (<u>link</u>)
- 2) Shipment weakness likely to persist into 1Q23E; Maintain HOLD 11 Jan 2023 (link)
- 3) Soft HLS/HCM in Aug; Still awaiting turning point 13 Sep 2022 (link)




Focus Charts

Figure 1: Sunny Optical revenue trend




Source: Company data, CMBIGM estimates

Figure 2: Sunny Optical GPM trend




Source: Company data, CMBIGM estimates

Figure 3: Sunny HCM shipment trend



Source: Company data, CMBIGM estimates

Figure 4: Sunny HLS shipment trend




Source: Company data, CMBIGM estimates

Figure 5: Sunny next-gen handset camera products



Source: Company data, CMBIGM estimates

Figure 6: Sunny opportunities in vehicle cameras



Source: Counterpoint, CMBIGM estimates



2H22 Results Preview

Figure 7: 2H22 results preview

, and the second	•					СМВІ		Consensus	
RMB mn	1H21	2H21	1H22	2H22	YoY	2H22E	Diff (%)	2H22E	Diff (%)
Revenue	19,833	17,663	16,972	16,225	-8%	12,841	26%	14,837	9%
Gross profit	4,946	3,790	3,522	3,083	-19%	2,642	17%	2,928	5%
Operating profit	3,345	2,506	1,798	1,216	-51%	1,319	-8%	1,330	-9%
Net profit	2,688	2,305	1,358	1,050	-54%	1,053	0%	1,125	-7%
EPS (RMB)	2.46	2.11	1.24	0.96	-54%	0.96	0%	0.99	-3%
Gross margin	24.9%	21.5%	20.8%	19.0%	-2.5 ppt	20.6%	-1.6 ppt	19.7%	-0.7 ppt
Operating margin	16.9%	14.2%	10.6%	7.5%	-6.7 ppt	10.3%	-2.8 ppt	9.0%	-1.5 ppt
Net margin	13.6%	13.1%	8.0%	6.5%	-6.6 ppt	8.2%	-1.7 ppt	7.6%	-1.1 ppt

Source: Company data, CMBIGM estimates

Figure 8: FY22 revenue breakdown

RMB mn	1H21	2H21	1H22	2H22E	YoY	FY21	FY22	YoY
Optical comp (VLS, HLS)	4,344	4,432	4,399	5,069	14%	8,776	9,468	8%
Auto lens shipment (mn unit)	37	31	38	41	35%	68	79	16%
ASP (RMB)	35.1	33.6	35.1	43.6	30%	34.4	39.6	15%
Handset lens Shipment (mn unit)	7,171	7,225	6,516	5,410	-25%	14,395	11,926	-17%
ASP (RMB)	3.6	3.1	3.0	2.1	-34%	3.3	2.6	-23%
Optoelectronic (HCM)	15,308	13,026	12,371	10,955	-16%	28,334	23,326	-18%
HCM shipment (mn unit)	361	312	289	228	-27%	674	517	-23%
ASP (RMB)	39.3	38.3	38.9	41.1	8%	38.8	39.9	3%
Optical instruments	182	206	202	202	-2%	387	403	4%
Total Revenue	19,833	17,663	16,972	16,225	-8%	37,497	29,813	-20%
Gross Margin								
Optical comp (VLS, HLS)	42.9%	35.9%	35.5%	31.5%	-4.4 ppt	39.5%	33.4%	-6.1 ppt
Optoelectronic (HCM)	14.8%	12.4%	11.6%	9.7%	-2.7 ppt	13.7%	10.7%	-3.0 ppt
Optical instruments	44.2%	49.3%	44.6%	46.3%	-3 ppt	45.1%	42.0%	-3.1 ppt
Blended GPM	24.9%	21.5%	20.8%	19.0%	-2.5 ppt	23.3%	19.9%	-3.4 ppt

Source: Company data, CMBIGM estimates



Valuation

Maintain HOLD with TP of HK\$92.51

We maintain HOLD with TP of HK\$92.51. We derived our 12-month TP from SOTP valuation methodology and our TP is based on weighted-average target P/E multiple of 23.6x FY23E EPS, in order to reflect 1) Sunny's diversification in multiple businesses with different growth profiles, and 2) visibility of product upcycles across different segments.

We assign 15x P/E to its CCM business to reflect its China No.1 position, product upcycle and advanced technology capacity. We assign 35x P/E for its vehicle lens business to reflect the high-margin and high-growth industry nature of vehicle lens (25% CAGR FY20-23E) and Sunny's No.1 global market share. We apply a 25x P/E to its handset lens segment given secular upgrade trend and continued share gains from peers.

Figure 9: Sunny Optical - SOTP valuation

% of FY23E Profit	FY23E EPS (RMB)	Target P/E
33.7%	1.10	15x
45.0%	1.47	25x
19.3%	0.63	35x
2.1%	0.07	25x
	3.26	23.6x
		92.51
	33.7% 45.0% 19.3%	33.7% 1.10 45.0% 1.47 19.3% 0.63 2.1% 0.07

Sources: Company data, CMBIGM estimates

Figure 10: Peers' valuation

			Market			Up/						
			Сар	Price	TP	Down	P/E	(x)	P/E	(x)	ROE	(%)
Company	Ticker	Rating	(US\$ mn)	(LC)	(LC)	-side	FY23E	FY24E	FY23E	FY24E	FY23E	FY24E
Sunny Optical	2382 HK	HOLD	12,160	87.0	92.5	6%	24.2	19.9	3.3	2.9	14.9	16.0
Q tech	1478 HK	BUY	627	4.2	5.2	25%	8.7	6.4	0.9	0.8	9.8	12.0
Cowell	1415 HK	NR	1,730	16.16	NA	NA	16.9	12.3	2.6	2.2	20.0	21.8
Truly	732 HK	NR	419	1.04	NA	NA	-	-	-	-	-	-
Catcher	2474 TT	NR	4,373	187.00	NA	NA	19.0	18.0	0.8	0.8	4.3	4.5
Largan	3008 TT	NR	9,743	2230.00	NA	NA	16.6	15.2	1.8	1.7	11.4	11.7
Lite-on	2301 TT	NR	5,399	69.80	NA	NA	11.4	10.1	1.9	1.9	17.6	19.4
Primax	4915 TT	NR	905	60.20	NA	NA	9.4	8.7	1.6	1.5	16.3	16.8
O-film	002456 CH	NR	2,373	5.01	NA	NA	-	86.4	4.4	4.1	(13.2)	0.8
			Average				15.1	22.1	2.2	2.0	10.0	12.7


Source: Bloomberg, CMBIGM estimates

Figure 11: 12M forward P/E band



Source: Bloomberg, CMBIGM estimates

Figure 12: 12M forward P/B band



Source: Bloomberg, CMBIGM estimates



Financial Summary

INCOME STATEMENT	2019A	2020A	2021A	2022E	2023E	2024E
YE 31 Dec (RMB mn)						
Revenue	37,849	38,002	37,497	29,813	32,213	37,781
Cost of goods sold	(30,098)	(29,304)	(28,761)	(23,649)	(25,192)	(29,366)
Gross profit	7,751	8,698	8,736	6,164	7,021	8,415
Selling expense	(279)	(313)	(274)	(266)	(235)	(283)
Admin expense	(650)	(719)	(758)	(772)	(709)	(793)
R&D expense	(2,209)	(2,499)	(2,642)	(2,560)	(2,384)	(2,758)
Others	205	698	789	558	670	691
Operating profit	4,806	5,877	5,851	3,117	4,364	5,272
Share of (losses)/profits of associates/JV	(6)	0	19	2	2	2
Net Interest income/(expense)	(250)	(224)	(230)	(240)	(264)	(291)
Pre-tax profit	4,550	5,653	5,640	2,879	4,101	4,983
Income tax	(531)	(703)	(579)	(424)	(476)	(578)
Minority interest	28	68	68	43	64	78
Net profit	4,019	4,950	5,061	2,454	3,626	4,405
Net dividends	623	799	974	470	695	844
BALANCE SHEET	2019A	2020A	2021A	2022E	2023E	2024E
YE 31 Dec (RMB mn)						
Current assets	22,446	25,630	27,989	24,035	31,701	31,571
Cash & equivalents	1,917	2,842	5,605	7,285	7,807	11,123
Account receivables	9,630	8,212	7,448	5,003	8,451	7,328
Inventories	5,146	5,783	5,482	2,293	5,989	3,665
ST bank deposits	21	238	1,112	1,112	1,112	1,112
Financial assets at FVTPL	5,663	8,480	8,314	8,314	8,314	8,314
Other current assets	69	74	28	28	28	28
Non-current assets	8,247	9,809	10,785	11,979	12,942	13,627
PP&E	6,567	7,513	8,303	9,550	10,497	11,144
Other non-current assets	1,680	2,295	2,481	2,429	2,445	2,483
Total assets	30,693	35,438	38,774	36,014	44,643	45,198
Current liabilities	12,630	13,411	11,873	7,129	12,828	9,822
Short-term borrowings	1,119	2,071	1,539	1,539	1,539	1,539
Account payables	11,322	10,733	9,869	5,163	10,849	7,816
Other current liabilities	5,622	9,223	15,493	22,182	19,427	26,021
Non-current liabilities	5,336	5,201	6,005	6,005	6,005	6,005
Long-term borrowings	0	0	700	700	700	700
Other non-current liabilities	5,336	5,201	5,305	5,305	5,305	5,305
Total liabilities	17,967	18,612	17,879	13,134	18,833	15,827
Share capital	105	105	105	105	105	105
Other reserves	12,448	16,492	20,483	22,423	25,290	28,773
Total shareholders equity	12,726	16,826	20,895	22,879	25,810	29,371
Minority interest	173	229	307	351	415	493
Total equity and liabilities	30,693	35,438	38,774	36,014	44,643	45,198



CASH FLOW	2019A	2020A	2021A	2022E	2023E	2024E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	4,550	5,643	5,640	2,879	4,101	4,983
Depreciation & amortization	1,227	1,570	1,638	1,753	2,053	2,353
Change in working capital	(1,477)	115	200	928	(1,457)	413
Others	361	(168)	(499)	(170)	(216)	(298)
Net cash from operations	4,662	7,160	6,979	5,390	4,481	7,451
Investing						
Capital expenditure	(2,760)	(2,271)	(2,498)	(3,000)	(3,000)	(3,000)
Others	(796)	(3,705)	5,400	0	0	0
Net cash from investing	(3,556)	(5,976)	2,902	(3,000)	(3,000)	(3,000)
Financing						
Dividend paid	(623)	(796)	(974)	(470)	(695)	(844)
Net borrowings	(382)	1,017	0	0	0	0
Share repurchases	(170)	(151)	0	0	0	0
Others	(266)	(291)	2,215	(240)	(264)	(291)
Net cash from financing	(1,441)	(222)	1,241	(710)	(959)	(1,135)
Net change in cash						
Cash at the beginning of the year	2,254	1,917	2,842	5,605	7,285	7,807
Exchange difference	(2)	(37)	(8,358)	0	0	0
Cash at the end of the year	1,917	2,842	5,605	7,285	7,807	11,123

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.